English
Русский 105-118 p.
The problem of secondary osteoporosis in various diseases is becoming a public health problem in all countries of the world, which is associated with the high prevalence of this condition among patients, regardless of gender, with chronic renal failure, in women in the postmenopausal period, as well as among patients with pemphigus complicated by the development of glucocorticoid osteoporosis. In this regard, we conducted a systematic literature search and a study of patients with these diseases in order to identify potential secondary osteoporosis. Literature searches were conducted in PubMed and Google Scholar for the keywords mineral metabolism, secondary osteoporosis, and biochemical characteristics. Based on the analysis of the literature data and the results of our scientific work, it seems possible to conclude that the diseases during treatment in all cases are subject to cor-rection. The patterns of mineral metabolism disorders were revealed, which are characteristic simultaneously for all 3 studied pathologies (violation of calcium and phosphorus parameters).
1. Al-Daghri N. M. et al. Inflammation as a contributing factor among postmenopausal Saudi women with oste-oporosis. Medicine. 2017. T. 96. № 4.
2. Ortiz A. et al. Epidemiology, contributors to, and clinical trials of mortality risk in chronic kidney failure. The lancet. 2014. T. 383. № 9931. S. 1831 – 1843.
3. Moe S. et al. Definition, evaluation, and classification of renal osteodystrophy: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney international. 2006. T. 69. № 11. S. 1945 – 1953.
4. Fang Y. et al. CKD-induced wingless/Integration1 inhibitors and phosphorus cause the CKD – mineral and bone disorder. Journal of the American Society of Nephrology. 2014. T. 25. № 8. S. 1760 – 1773.
5. Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group et al. KDIGO clinical prac-tice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney international. Supplement. 2009. № 113. S. S1.
6. Scialla J.J. et al. Mineral metabolites and CKD progression in African Americans. Journal of the American Society of Nephrology. 2013. T. 24. № 1. S. 125 – 135.
7. Hill K. M. et al. Oral calcium carbonate affects calcium but not phosphorus balance in stage 3-4 chron-ic kid-ney disease. Kidney international. 2013. T. 83. № 5. S. 959 – 966.
8. Wesseling K., Bakkaloglu S., Salusky I. Chronic kidney disease mineral and bone disorder in children. Pedi-atric Nephrology. 2008. T. 23. № 2. S. 195 – 207.
9. Evenepoel P. et al. A randomized study evaluating cinacalcet to treat hypercalcemia in renal transplant recipi-ents with persistent hyperparathyroidism. American Journal of Transplantation. 2014. T. 14. № 11. S. 2545 – 2555.
10. Malluche H.H., Porter D.S., Pienkowski D. Evaluating bone quality in patients with chronic kidney disease. Nature Reviews Nephrology. 2013. T. 9. № 11. S. 671.
11. Kawakami T., Ren S., Duffield J. S. Wnt signalling in kidney diseases: dual roles in renal injury and repair. The Journal of pathology. 2013. T. 229. № 2. S. 221 – 231.
12. Morena M. et al. Osteoprotegerin and sclerostin in chronic kidney disease prior to dialysis: potential partners in vascular calcifications. Nephrology Dialysis Transplantation. 2015. T. 30. № 8. S. 1345 – 1356.
13. Pelletier S. et al. The relation between renal function and serum sclerostin in adult patients with CKD. Clini-cal Journal of the American Society of Nephrology. – 2013. – T. 8. – №. 5. – S. 819-823.
14. Oommen A., AlZahrani I. Prevalence of osteoporosis and factors associated with osteoporosis in women above 40 years in the Northern Part of Saudi Arabia. Int J Res Med Sci. – 2014. – T. 2. – №. 1. – S. 274.
15. Ahmatov V.Yu. i dr. Funkcional'naya aktivnost' nejtrofilov i pokazateli fosforno-kal'cievogo gomeostaza u bol'nyh hronicheskoj pochechnoj nedostatochnost'yu, nahodyashchihsya na pro-grammnom gemodialize. Vestnik CHelyabinskoj oblastnoj klinicheskoj bol'nicy. 2016. № 1. S. 29 – 32.
16. Ufimceva M.A. i dr. Osteoporoz, vyzvannyj dlitel'nym priemom glyukokortikoidov, u bol'-nyh akantolitich-eskoj puzyrchatkoj. Vestnik dermatologii i venerologii. 2016. № 3. S. 56 – 61.
17. Kutasevich YA.F. i dr. Korrekciya narushenij remodelirovaniya kostnoj tkani pri dlitel'noj kortikosteroidnoj terapii. Mezhdunarodnyj endokrinologicheskij zhurnal. 2019. T. 15. № 2. S. 93 – 98.
18. Mazurov V.I., Sergeeva A.A., Trofimov E.A. Rol' preparatov kal'ciya v kompleksnom lechenii postmeno-pauzal'nogo osteoporoza. Medicinskij sovet. 2016. № 5. S. 114 – 119.
19. Eliseeva L.N., ZHdamarova O.I., Baste Z.A. Primenenie mineral'no-vitaminnogo kompleksa Kal'cemin Ad-vans dlya profilaktiki i lecheniya osteoporoza i drugih patologicheskih sostoyanij organizma cheloveka. Russkij medicinskij zhurnal. 2015. T. 23. № 10. S. 560 – 564.
20. Gromova O.A., Torshin I.Yu., Limanova O.A. Kal'cij i ego sinergisty v podderzhke struktury soedinitel'noj i kostnoj tkani. Lechashchij vrach. 2014. T. 5. S. 69 – 76.
2. Ortiz A. et al. Epidemiology, contributors to, and clinical trials of mortality risk in chronic kidney failure. The lancet. 2014. T. 383. № 9931. S. 1831 – 1843.
3. Moe S. et al. Definition, evaluation, and classification of renal osteodystrophy: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney international. 2006. T. 69. № 11. S. 1945 – 1953.
4. Fang Y. et al. CKD-induced wingless/Integration1 inhibitors and phosphorus cause the CKD – mineral and bone disorder. Journal of the American Society of Nephrology. 2014. T. 25. № 8. S. 1760 – 1773.
5. Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group et al. KDIGO clinical prac-tice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney international. Supplement. 2009. № 113. S. S1.
6. Scialla J.J. et al. Mineral metabolites and CKD progression in African Americans. Journal of the American Society of Nephrology. 2013. T. 24. № 1. S. 125 – 135.
7. Hill K. M. et al. Oral calcium carbonate affects calcium but not phosphorus balance in stage 3-4 chron-ic kid-ney disease. Kidney international. 2013. T. 83. № 5. S. 959 – 966.
8. Wesseling K., Bakkaloglu S., Salusky I. Chronic kidney disease mineral and bone disorder in children. Pedi-atric Nephrology. 2008. T. 23. № 2. S. 195 – 207.
9. Evenepoel P. et al. A randomized study evaluating cinacalcet to treat hypercalcemia in renal transplant recipi-ents with persistent hyperparathyroidism. American Journal of Transplantation. 2014. T. 14. № 11. S. 2545 – 2555.
10. Malluche H.H., Porter D.S., Pienkowski D. Evaluating bone quality in patients with chronic kidney disease. Nature Reviews Nephrology. 2013. T. 9. № 11. S. 671.
11. Kawakami T., Ren S., Duffield J. S. Wnt signalling in kidney diseases: dual roles in renal injury and repair. The Journal of pathology. 2013. T. 229. № 2. S. 221 – 231.
12. Morena M. et al. Osteoprotegerin and sclerostin in chronic kidney disease prior to dialysis: potential partners in vascular calcifications. Nephrology Dialysis Transplantation. 2015. T. 30. № 8. S. 1345 – 1356.
13. Pelletier S. et al. The relation between renal function and serum sclerostin in adult patients with CKD. Clini-cal Journal of the American Society of Nephrology. – 2013. – T. 8. – №. 5. – S. 819-823.
14. Oommen A., AlZahrani I. Prevalence of osteoporosis and factors associated with osteoporosis in women above 40 years in the Northern Part of Saudi Arabia. Int J Res Med Sci. – 2014. – T. 2. – №. 1. – S. 274.
15. Ahmatov V.Yu. i dr. Funkcional'naya aktivnost' nejtrofilov i pokazateli fosforno-kal'cievogo gomeostaza u bol'nyh hronicheskoj pochechnoj nedostatochnost'yu, nahodyashchihsya na pro-grammnom gemodialize. Vestnik CHelyabinskoj oblastnoj klinicheskoj bol'nicy. 2016. № 1. S. 29 – 32.
16. Ufimceva M.A. i dr. Osteoporoz, vyzvannyj dlitel'nym priemom glyukokortikoidov, u bol'-nyh akantolitich-eskoj puzyrchatkoj. Vestnik dermatologii i venerologii. 2016. № 3. S. 56 – 61.
17. Kutasevich YA.F. i dr. Korrekciya narushenij remodelirovaniya kostnoj tkani pri dlitel'noj kortikosteroidnoj terapii. Mezhdunarodnyj endokrinologicheskij zhurnal. 2019. T. 15. № 2. S. 93 – 98.
18. Mazurov V.I., Sergeeva A.A., Trofimov E.A. Rol' preparatov kal'ciya v kompleksnom lechenii postmeno-pauzal'nogo osteoporoza. Medicinskij sovet. 2016. № 5. S. 114 – 119.
19. Eliseeva L.N., ZHdamarova O.I., Baste Z.A. Primenenie mineral'no-vitaminnogo kompleksa Kal'cemin Ad-vans dlya profilaktiki i lecheniya osteoporoza i drugih patologicheskih sostoyanij organizma cheloveka. Russkij medicinskij zhurnal. 2015. T. 23. № 10. S. 560 – 564.
20. Gromova O.A., Torshin I.Yu., Limanova O.A. Kal'cij i ego sinergisty v podderzhke struktury soedinitel'noj i kostnoj tkani. Lechashchij vrach. 2014. T. 5. S. 69 – 76.